| [1] |
Ferlay J, Colombet M, Soerjomataram I, et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018 [J]. Eur J Cancer, 2018, 103: 356-387
|
| [2] |
陈磊, 徐杰茹, 王冕, 等. 1990-2019年中国肾癌死亡趋势及其年龄-时期-队列分析[J]. 中华疾病控制杂志, 2021, 25(9): 1026-1033, 1111.
|
| [3] |
Vasudev NS, Wilson M, Stewart GD, et al. Challenges of early renal cancer detection: symptom patterns and incidental diagnosis rate in a multicentre prospective UK cohort of patients presenting with suspected renal cancer [J]. BMJ open, 2020, 10(5): e035938.
|
| [4] |
Ma H, Shen G, Liu B, et al. Diagnostic performance of 18F-FDG PET or PET/CT in restaging renal cell carcinoma: a systematic review and meta-analysis [J]. Nucl Med Commun, 2017, 38(2): 156-163.
|
| [5] |
Jena R, Narain TA, Singh UP, et al. Role of positron emission tomography/computed tomography in the evaluation of renal cell carcinoma [J]. Indian J Urol, 2021, 37(2): 125-132.
|
| [6] |
Silverman SG, Pedrosa I, Ellis JH, et al. Bosniak classification of cystic renal masses, version 2019: An update proposal and needs assessment [J]. Radiology, 2019, 292(2): 475-488.
|
| [7] |
Marconi L, Dabestani S, Lam TB, et al. Systematic review and meta-analysis of diagnostic accuracy of percutaneous renal tumour biopsy [J]. Eur Urol, 2016, 69(4): 660-673.
|
| [8] |
Moch H, Cubilla A L, Humphrey PA, et al. The 2016 WHO classification of tumours of the urinary system and male genital organs-part A: Renal, penile, and testicular tumours [J]. Eur Urol, 2016, 70(1): 93-105.
|
| [9] |
Delahunt B, Eble JN, Samaratunga H, et al. Staging of renal cell carcinoma: current progress and potential advances [J]. Pathology, 2021, 53(1): 120-128.
|
| [10] |
Maclennan S, Imamura M, Lapitan MC, et al. Systematic review of oncological outcomes following surgical management of localised renal cancer [J]. Eur Urol, 2012, 61(5): 972-993.
|
| [11] |
Capitanio U, Terrone C, Antonelli A, et al. Nephron-sparing techniques independently decrease the risk of cardiovascular events relative to radical nephrectomy in patients with a T1a-T1b renal mass and normal preoperative renal function [J]. Eur Urol, 2015, 67(4): 683-689.
|
| [12] |
Alam R, Patel HD, Osumah T, et al. Comparative effectiveness of management options for patients with small renal masses: a prospective cohort study [J]. BJU Int, 2019, 123(1): 42-50.
|
| [13] |
Sprenkle PC, Power N, Ghoneim T, et al. Comparison of open and minimally invasive partial nephrectomy for renal tumors 4-7 centimeters [J]. Eur Urol, 2012, 61(3): 593-599.
|
| [14] |
Badalato GM, Kates M, Wisnivesky JP, et al. Survival after partial and radical nephrectomy for the treatment of stage T1bN0M0 renal cell carcinoma (RCC) in the USA: a propensity scoring approach [J]. BJU Int, 2012, 109(10): 1457-1462.
|
| [15] |
Bedke J, Albiges L, Capitanio U, et al. 2021 Updated European Association of Urology Guidelines on the use of adjuvant pembrolizumab for renal cell carcinoma [J]. Eur Urol, 2022, 81(2): 134-137.
|
| [16] |
Bedke J, Albiges L, Capitanio U, et al. The 2021 Updated European Association of Urology Guidelines on renal cell carcinoma: immune checkpoint inhibitor-based combination therapies for treatment-naive metastatic clear-cell renal cell carcinoma are standard of care [J]. Eur Urol, 2021, 80(4): 393-397.
|
| [17] |
Choueiri TK, Tomczak P, Park SH, et al. Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma [J]. N Engl J Med, 2021, 385(8): 683-694.
|
| [18] |
Bex A, Albiges L, Ljungberg B, et al. Updated European Association of Urology Guidelines for cytoreductive nephrectomy in patients with synchronous metastatic clear-cell renal cell carcinoma [J]. Eur Urol, 2018, 74(6): 805-809.
|
| [19] |
Dabestani S, Marconi L, Hofmann F, et al. Local treatments for metastases of renal cell carcinoma: a systematic review [J]. Lancet Oncol, 2014, 15(12): e549-561.
|
| [20] |
Powles T, Albiges L, Staehler M, et al. Updated European Association of Urology Guidelines: recommendations for the treatment of first-line metastatic clear cell renal cancer [J]. Eur Urol, 2018, 73(3): 311-315.
|
| [21] |
Ko JJ, Xie W, Kroeger N, et al. The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study [J]. Lancet Oncol, 2015, 16(3): 293-300.
|
| [22] |
Fernández-Pello S, Hofmann F, Tahbaz R, et al. A systematic review and meta-analysis comparing the effectiveness and adverse effects of different systemic treatments for non-clear cell renal cell carcinoma [J]. Eur Urol, 2017, 71(3): 426-436.
|
| [23] |
Pal SK, Tangen C, Thompson IM Jr, et al. A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial [J]. Lancet, 2021, 397(10275): 695-703.
|
| [24] |
Rieken M, Kluth LA, Fajkovic H, et al. Predictors of cancer-specific survival after disease recurrence in patients with renal cell carcinoma: the effect of time to recurrence [J]. Clin Genitourin Cancer, 2018, 16(4): e903-e908.
|
| [25] |
Beisland C, Guðbrandsdottir G, Reisæter LA, et al. A prospective risk-stratified follow-up programme for radically treated renal cell carcinoma patients: evaluation after eight years of clinical use [J]. World J Urol, 2016, 34(8): 1087-1099.
|
| [26] |
Scoll BJ, Wong YN, Egleston BL, et al. Age, tumor size and relative survival of patients with localized renal cell carcinoma: a surveillance, epidemiology and end results analysis [J]. J Urol, 2009, 181(2): 506-511.
|